FDC2024-10-012024-12-31 FDC2024-10-012024-12-31 FDC2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member FDC2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member FDC2024-12-31 FDC2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member FDC2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member FDC2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member FDC2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 531599 FDC NOTLISTED FDC Limited Equity 2024-04-01 2025-03-31 2025-02-12 2025-02-07 INR Lakhs Third quarter 12:30:00 14:50:00 2025-02-12 2025-02-12 Not applicable Single segment npharmaceutical 2024-10-01 2024-12-31 Unaudited Consolidated 4641131000.00 188283000.00 4829414000.00 1489088000.00 259673000.00 -139555000.00 1185983000.00 9478000.00 133553000.00 1379412000.00 4317632000.00 511782000.00 0.00 511782000.00 135711000.00 5668000.00 141379000.00 0.00 370403000.00 0.00 0.00 0.00 0.00 370403000.00 4444000.00 374847000.00 374847000.00 0.00 374847000.00 0.00 162810000.00 1 2.28 2.28 0.00 0.00 2.28 2.28 1. The above unaudited consolidated financial results which are published in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’) for the quarter and nine months ended December 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company at their meeting held on February 12, 2025. The Statutory Auditors have carried out a limited review of the above results and have expressed an unmodified review conclusion. 2. The Parent Company recognized a fair value loss of Rs. 541.26 lakhs under other expenses in the quarter ended December 31, 2024 in accordance with Ind AS 109 (Financial Instruments). However, for the nine months ended December 31, 2024, a net fair value gain of Rs. 2,627.10 lakhs was recorded under Other Income. Due to this treatment, the quarterly numbers may not be directly additive to the year-to-date (YTD) numbers, as fair value changes are recognized based on market conditions prevailing at different reporting dates. 3. During the current quarter, the Parent Company has paid an Interim Dividend of Rs. 5/- per equity share of face value Rs.1/- each for the Financial Year 2024-25, as approved by the Board of Directors of the Parent Company at their meeting held on November 6, 2024. 4. During the previous year, the Parent Company had completed the buyback of 31,00,000 equity shares having face value of Rs. 1/- each at a price of Rs. 500/- per share on September 13, 2023. The number of equity shares post buyback stands reduced to 16,28,10,084 shares having face value of Rs. 1/- each. Accordingly, the paid-up share capital also stands reduced to Rs. 16,28,10,084. 5. The Group has only one segment of activity namely “Pharmaceuticals”. 6. The above results are also available on the website of the Parent Company i.e. www.fdcindia.com and on the website of the Stock Exchanges i.e. www.nseindia.com and www.bseindia.com. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 16162311000.00 765521000.00 16927832000.00 4246066000.00 948175000.00 555122000.00 3607614000.00 33174000.00 381703000.00 4116886000.00 13888740000.00 3039092000.00 0.00 3039092000.00 702896000.00 55028000.00 757924000.00 0.00 2281168000.00 0.00 0.00 0.00 0.00 2281168000.00 23733000.00 2304901000.00 2304901000.00 0.00 2304901000.00 0.00 162810000.00 1 14.02 14.02 0.00 0.00 14.02 14.02 Other expenses 1379412000.00 Other expenses 4116886000.00 Items that will not be reclassified subsequently to profit or loss 413000.00 Items that will not be reclassified subsequently to profit or loss 3787000.00 413000.00 3787000.00 62000.00 479000.00 Items that will be reclassified to profit or loss 4093000.00 Items that will be reclassified to profit or loss 20425000.00 4093000.00 20425000.00 0.00 0.00